Search 

JOT is a virtual company with its base operation in Jupiter, FL. JOT is in position to quickly come to market with a platform product effective to treat 12 or more indications including Alzheimer’s Disease. The proprietary patented product, JOTROL, is very safe, oral, naturally based and multi-functional. JOTROL will be very effective with high social and economic impact within a reasonable timeframe. Relationships have been developed with scientists at various institutions, such as University of Miami (“UM”), MIT, Harvard, Georgetown University and Murdoch Childrens Research Institute, AU. This setup has made it possible to gain access to laboratory work, scientific information, pre-clinical development and scientific expertise in an extremely cost effective and efficient way. JOT will conclude clinical trials by utilizing a contract manufacturer and Clinical Research Organizations, involvement by its scientific advisors as well as support from patient organizations thereby keeping its fixed overhead extremely low for a Biotech company. A Phase I trial is presently ongoing with results expected in Q1,2021. Two Phase II rare disease trials, are expected to be started in H2 of 2021 with possible accelerated approvals from FDA. Partial financing for those are expected to be received from NIH. A Phase II trial in Alzheimer’s is also planned to be executed in parallel. Financing for the Phase I study has been granted by NIA (National Institute of Aging). Financing for a larger Phase II study is also expected to be financed by a NIA consortium (up to $75 million). JOT is prepared to add a commercial organization to market its product in North America while out-licensing marketing and sales operations for the rest of the world.

Kymeris Therapeutics (Canada) has exlusive license to a ground-breaking cell-based immunotherapeutic product for clinical development in cancer. This multivalent anti-cancer platform integrates multiple mechanisms in one modifiable platform. The product is tumor-homing, disables the local tumor defenses and expresses encoded biodrugs in the cancer - but not systemically.

*  We are seeking partners with small molecule or antibody (or any encodable peptide or protein) that would have an enabling platform compared to intravenous or intratumoral formulations.

*  We are also seeking strategic investors in the platform that has extremely high potential in future products, adaptable against almost any solid cancer.

------------------------------------------------------------------

The platform can enable, or enhance, additional small molecule, antibody, peptide or cytokine agents.  It is a preclinical late-stage firm that has discovered and developed a First-in-Class immunotherapeutic platform based on non-pathogenic eukaryotes (nucleated cells, non-viral, non-bacterial). Our platform is original with the first scientific paper just published in November 2020 by the Journal of Immunotherapy of Cancer (BMJ), and our first scientific presentation at the 2020 Annual Meeting of the SITC where we presented recent report on a derivative that secreted human IL-15 within tumor, but devoid of serum detection of the cytokine.

The platform would be a paradigm shift from "reductive" (targeted, mono-mechanism) approaches, and can be encoded with additional molecular therapies to more comprehensively face the complex of solid cancer defenses. Encoding any biological agent (small molecule, antibody, antigen, cytokine...), could enable that agent for a wider scope of applications,  enhanced effect and much safer profile.  In addition, the platform shows abscopal effect, an ability to reach tumors after administration from a distance (subcutaneous or mucosal).

The platform has shown the following characteristics:

1. Tumor-tropism / Cancer-agnostic. Homing to tumor occurred in the absence of a cancer antigen marker (TAA or TSA), and may even work in tumors that are not easily "targetable", such as "cold", lacking cancer markers, heterogeneic or mutating tumors. One oncologist remarked, "This turns "cold" tumors "hot" ".The agents have had effect at distance from tumor site when administered subcutaneously or mucosally. 

 2. Tumor-infiltration + TME counteraction. The agents bear a specialized "universal key" to gain entry into mammalian cell in an active process; no specific  receptor needed. In addition, the agents are able to reprogram tolerogenic cells into a state of immune competence i.e. to overcome cancer-induced immune suppression within the tumor.

3. Intra-cancer delivery of any payload/s. Obligate intracellular microbes, the agents infect cancer cells and replicate, expressing encoded biodrugs. The replication continues as long as there is cancer tissue to infect and/or the TME has not been disabled.  Any agents outside of the TME were naturally cleared in under 10 days.

Founded in 1908, LEO Pharma is an independent, research-based pharmaceutical company, wholly owned by The LEO Foundation and is headquartered in Ballerup, Denmark. LEO Pharma is a leader in medical dermatology and developes, manufactures and markets pharmaceutical drugs for medical dermatology and thrombosis in more than 100 countries globally. We offer patients and physicians highly innovative and well-established products in Psoriasis, Atopic Dermatitis, Eczema, Acne, Rosacea.
LEO Pharma is continuously striving to advance innovation to bring best-in-class and first-in-class medicines in medical dermatology and rare dermatological diseases to create a solid pipeline of assets. LEO Pharma’s mission is to provide people with healthy skin and is has a global dermatology reach employing approximately 6,000 employees worldwide. We serve approximately 92 million patients in 2019 with ambition to serve 125 million patients by 2025.
To realize our vision of becoming the preferred dermatology care partner improving people’s lives around the world, we are constantly looking to collaborate with other companies, Universities to offer patients with therapies that address unmet medical needs in dermatology.

We are keen for In-Licensing Assets for Global and Regional Rights for following: (1) Chinese Rights: innovative (first-in-class or best-in-class) late stage assets (Phase 3 or launched in US, EU or Japan) in medical dermatology or rare dermatological diseases (2) Global Rights: innovative (first-in-class or best-in-class) assets (Pre-clinical through phase III) in medical dermatology or rare dermatological diseases from Asian Biotech companies, Research, and/or academic institutes/universities. (3) VC companies: Who have in their portfolio, companies that have medical dermatology products in their pipeline for China or Global markets (4) Keen to Science and Tech parks in China: Who have companies conducting cutting edge research in medical dermatology
In addition we LEO Pharma has two early stage assets available for partnering.

LEO 142397 (LP0184) is an oral, super selective JAK 1 inhibitor for inflammatory diseases. Product is ready for phase 1 studies. Compound is available for global licensing or acquisition.

LEO 134310 (LP0155) is a SEGRA compound. It is topical, supersoft, non-steroidal Glucocorticoid Receptor (GR) agonist with improved systemic and local safety profile. LP0155 has demonstrated efficacy in clinical phase 1 studies. Compound is available for global licensing or acquisition.

Libera Bio develops a new family of cancer treatments based on its patented actively targeted delivery technology to intracellular targets (MPN – Multifunctional Polymeric Nanocapsules) and on novel monoclonal antibodies (e.g. anti KRAS), with the goal to have them commercialized by large biopharma companies after regulatory approval for clinical trials or early proof-of-concept in humans.

Libera Bio lead candidate aims at providing a new treatment for those highly prevalent and aggressive cancers which are driven by KRAS mutations, such as pancreatic cancer, lung cancer and colorectal cancer.

Company:
Maculus Therapeutix is a preclinical-stage biopharmaceutical company focused on finding practical solutions to treat chronic diseases of the retina and optic nerve such as wetAMD (Age related Macular Degeneration) in the Ophthalmology space with a novel tunable biodegradable proprietary product – MacuBloc™ capable of delivering any FDA approved drugs for Wet AMD to the site of the disease. With its unique suitability for targeted and extended delivery of drugs to back of the human eyes, MacuBloc™ offers significant benefits to Wet AMD patients over existing products: a single intravitreal injection that lasts an year instead of the current 10-12 monthly injections plus significant potential reduction in inflammation, infection, doctor visits and total cost of care compared to current practice.

Market:
The global market size of Age-Related Macular Degeneration (AMD) is currently $7.7B, growing at 7.6% CAGR and is expected to reach a value of $11B by 2025. Current standard of care involves 10-12 monthly injections with a 30 gauge syringe needle going through the eye sclera, often resulting post-injection pain and possible infection due to repeated injections in a small area as well as ruptured blood vessels in the sclera. By reducing the number of injections from 10+ to just ONE, MacuBloc™ formulation is likely to be a treatment of choice.

maintect GmbH was founded 2018 in collaboration with Mainz University Medical Center Germany by ophthalmological scientists.
maintect is developing an innovative antibody treatment for a new target instead of the well-known VEGF in wAMD (wet age-related-macular-degeneration, one of the most frequent causes of blindness). This new antibody will help the patients who don’t benefit from anti-VEGF treatment and all others. maintect applied already for patent in several countries. Combination with anti-VEGF is also an option. In parallel, the company is developing a companion diagnostic kit using lateral flow assays for anti-VEGF treatment in wAMD. This test will determine which patients will benefit most from the new treatment and will facilitate the market entrance. Furthermore, the company is interested in contract research and collaborations in building diagnostic kits.

Investment banking boutique specialized in cross-border medical device transactions.
We would like to bring to your next events exclusive opportunities from Western companies in the fields of: robotics, cancer screening, liver disease diagnostic, robotics, cardiovascular and respiratory

MedWorld Advisors is an international M&A Services Firm. We represent medical technology companies from the US, EU and Israel that want to enter the China market. We facilitate licensing, commercialization and acquisition deals between our clients and larger companies / investors in China. We are based in Boston in the U.S. We also have an operation in Hong Kong to help facilitate deals, as helpful.

MSL Pharma is an early-stage pharma company that performs ideation, analysis and identification of the underlying pathological pathways to determine how to treat diseases. The Company holds exclusive licenses from the Hebrew University & Ben-Gurion University of the Negev. There are data, patents and publications concerning the technologies.

As an early-stage company, in order to reduce overhead costs, we effectively act as the project manager – we plan the assays and subcontract the early development stages to university labs, and the later stages to CROs that specialize in the different fields. The Company monitors the results, determines next steps and fundraises for the next phases of development. We believe that working with leading experts at CROs is critical for success.

The Company has licenses for platform technologies which are progressing to several different projects; as such it is planning to out-license at various stages of development.

Synthesis of cyclic peptides which are peptidomimetics
MSL Pharma has the capability to identify “active regions” of proteins and peptides, to isolate them and to turn them into cyclic peptides which are selective for the desired receptors and stable, thereby preventing off-target activation and adverse effects (see Asset, Table 1).

Drug delivery systems for peptides and other molecules
MSL Pharma has two technologies for drug delivery (see Mode of Delivery, Table 1) that achieve unprecedented bioavailability:
1. Lipophilic prodrug charge masking (LPCM) technology for the oral delivery of peptides. This technology makes a chemical modification in a peptide to be converted to oral delivery, to produce a prodrug of this peptide. This causes it to be absorbed through the intestinal cell and once the prodrug enters the blood stream, it converts back to the original peptide. Typically, the Pgp Efflux system limits the prodrug absorption; we have overcome this with an approved self-assembling PNL (pro-nano liposphere) encapsulation system, itself a self-nanoemulsifying drug delivery system (SNEDDS), which increases prodrug solubility and inhibits the Pgp Efflux system.

2. A novel nanoparticle formulation called AmyloLipid Nanovesicles which is constructed of natural materials and therefore safe ,biodegradable and has an advantage for the delivery of peptides. This technology is used also for the delivery of other molecules, can be used for nose-to-brain, sublingual, transdermal and probably also oral delivery, and can be applied to our assets (Table 1) or existing assets (Table 2).

A novel smart multi-armed linker for targeted drug delivery
Our linker can be used for peptide-drug conjugates (PDCs), antibody-drug conjugates (ADCs) and nanoparticle-drug conjugates (NDCs). Our linker releases the payload (chemotherapeutic drug or fluorescent) only in the tumor cells and can bind up to three payloads (see Table 3). We have demonstrated that using two or three different drug payloads kills the tumor cells more potently and with less drug resistance developing.

Discovery of novel peptides for peptide-drug conjugates
We have technologies to synthesize novel peptides which will bind to receptors overexpressed in certain tumors so that we will be able to use them for synthesizing peptide-drug conjugates (PDCs) to diagnose and treat different tumors. We already have at our disposal peptides that bind to the five different somatostatin receptors (overexpressed in pancreatic, gallbladder, breast, ovary, prostate, melanoma, lymphoma, glioblastoma, colon and non-small-cell lung tumors) and to certain integrin receptors (overexpressed in tumors such as breast, glioblastoma, leukemic cells).